GSK's Open Lab Looking To Synch Big Pharma Neglected Disease Initiatives
This article was originally published in The Pink Sheet Daily
Executive Summary
Tres Cantos lab's initial focus is on on malaria, tuberculosis, and kinetoplastid diseases.
You may also be interested in...
Glaxo’s Tres Cantos Open Lab Trawls For Answers To Neglected Diseases
Tres Cantos, Spain facility hopes to move molecules into clinical research in 2013/2014. Wellcome Trust has just pledged £5 million to help support the lab’s open R&D programs.
Pre-Competitive Collaboration Would Help Pharmaceutical Productivity Crisis - If Lawyers Could Get Out Of The Way
CAMBRIDGE, Mass. - Greater R&D collaboration was the theme of the day at the star-studded U.S.-India Chamber of Commerce biopharma and healthcare summit
GlaxoSmithKline Offering Free Access to Potential Malaria Compounds
GSK CEO Andrew Witty is making another push for cooperation in malaria drug research, offering access to 13,500 compounds and the chance for 60 scientists to work at its research centre in Spain.